A Phase 3 interventional study of Brexpiprazole and Seroquel XR in Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 76 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-06-08.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one has the largest enrollment, is one of 2 that started in 2012, is one of 16 in phase 3, and was the 7th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,182 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 2nd largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2012, is one of 23 in phase 3, and was the 23rd registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
This is a trial designed to assess the safety and efficacy of brexpiprazole (flexible dose) as adjunctive therapy to an assigned known anti-depressant in depressed subjects. The trial consists of a continuous 18-week double-blind treatment period with a 30-day follow-up. Subjects who complete all trial visits through the Week 18 visit may be offered entry into an optional open-label rollover trial.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
This study's enrollment of 2,182 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching Placebo and assigned ADT
Drug: Placebo
Brexpiprazole, flexible dose and assigned ADT
Drug: Brexpiprazole
Seroquel XR, flexible dose and assigned ADT
Drug: Seroquel XR
tablet/capsule
Also known as: OPC-34712
tablet/capsule
tablet/capsule
Montgomery Asberg Depression Rating Scale (MADRS)
To determine the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy by assessment of MADRS total score. The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.
Time frame: Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).
Sheehan Disability Scale (SDS)
To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale is a measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains ( work/social life/family life/home responsibilities). The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. Scores of 5 and above are associated with significant functional impairment. Additionally, SDS included 2 questions related to productivity losses due to the psychiatric symptoms and impairment.
Time frame: Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).
Change From End of Phase A in MADRS Total Score for Trial Week 2 and Week 4.
Change from end of Phase A in MADRS Total Score. The MADRS was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.
Time frame: Change from baseline to week 2 and week 4 in Phase B (week 10/12 and week 12/14)
Clinical Global Impression Score
Mean change from end of Phase A in Clinical Global Impression - Severity of Illness scale (CGI-S) score and Improvement scale (CGI-I) during double-blind randomized Phase B treatment. CGI-S score assessed how mentally ill the patient was at that time. CGI-S score is calculated from 0 to 7 (0 indicates not assessed 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and7 indicated among the most extremely ill patient). CGI-I score is compared to his/her condition at baseline, how much has the patient changed. CGI-I score is calculated from 0 to 7 (0 indicates not assessed and 7 indicates very much worse).
Time frame: From randomization to Phase B week 6 (14/16 weeks after randomization).
MADRS Response at Week 6
MADRS Response Rate, where response was defined as 50% reduction in MADRS Total Score, during double-blind randomized Phase B treatment.
Time frame: Phase B week 6 (14/16 weeks after randomization).
Number of Participants With MADRS
MADRS Remission Rate, where remission was defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score, for every trial week visit during double-blind randomized Phase B treatment.
Time frame: Phase B week 6 (14/16 weeks after randomization).
CGI-I Response Rate
CGI-I Response rate, where response was defined as a CGI-I score of 1 or 2 (very much improved or much improved), during double-blind randomized Phase B treatment.
Time frame: Phase B week 6 (14/16 weeks after randomization).
Number of Participants With Adverse Events
To evaluate the safety and tolerability of brexpiprazole (flexible dose) as adjunctive therapy to ADT in the proposed subject population with MDD as AE variables.
Time frame: From screening (Day -28 to Day-1) upto post treatment follow-up.
Sheehan Disability Scale (SDS) Individual Item Scores.
To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale (a self rated questionnaire) was used for measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains (work/school work, social life/leisure activities and family life/home responsibilities). All domains were rated on a score scale ranged from 0 (no impairment) to 10 (most severe). Score of 5 and above indicated significant functional impairment. A total score was addition of the 3 individual scores and the total score ranged from 0 (no impairment) to 30 (most severe).
Time frame: Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).
Trial was conducted at 75 trial sites in 7 countries (United States, Russia, Poland, France, Serbia,Germany \& Canada). Phase A non-responders entered Phase B (503 subjects randomized in 2:2:1 (197+100+206) ratio - brexpiprazole/Seroquel extended release tablets/placebo +ADT).
| Milestone | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| Started | 197 | 100 | 206 |
| Completed | 171 | 86 | 186 |
| Not completed | 26 | 14 | 20 |
To determine the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy by assessment of MADRS total score. The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.
| Units on a scale | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| Montgomery Asberg Depression Rating Scale (MADRS) | -6.04 ± 0.43 | -4.86 ± 0.57 | -4.57 ± 0.41 |
To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale is a measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains ( work/social life/family life/home responsibilities). The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. Scores of 5 and above are associated with significant functional impairment. Additionally, SDS included 2 questions related to productivity losses due to the psychiatric symptoms and impairment.
| units on a scale | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| Sheehan Disability Scale (SDS) | -0.97 ± 0.12 | -0.32 ± 0.16 | -0.74 ± 0.11 |
Change from end of Phase A in MADRS Total Score. The MADRS was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.
| units on a scale | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| Phase B Week 2 | -2.57 ± 0.32 | -2.26 ± 0.41 | -1.04 ± 0.31 |
| Phase B Week 4 | -4.39 ± 0.39 | -3.30 ± 0.51 | -3.22 ± 0.37 |
Mean change from end of Phase A in Clinical Global Impression - Severity of Illness scale (CGI-S) score and Improvement scale (CGI-I) during double-blind randomized Phase B treatment. CGI-S score assessed how mentally ill the patient was at that time. CGI-S score is calculated from 0 to 7 (0 indicates not assessed 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and7 indicated among the most extremely ill patient). CGI-I score is compared to his/her condition at baseline, how much has the patient changed. CGI-I score is calculated from 0 to 7 (0 indicates not assessed and 7 indicates very much worse).
| Mean score | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| CGI-Severity of Illness Scale | 3.98 ± 0.56 | 4.07 ± 0.58 | 4.02 ± 0.58 |
| CGI-Improvement Scale Score | 2.55 ± 0.84 | 2.71 ± 0.87 | 2.74 ± 0.83 |
MADRS Response Rate, where response was defined as 50% reduction in MADRS Total Score, during double-blind randomized Phase B treatment.
| Participants | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| MADRS Response at Week 6 | 20 | 8 | 14 |
MADRS Remission Rate, where remission was defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score, for every trial week visit during double-blind randomized Phase B treatment.
| Participants | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| Number of Participants With MADRS | 13 | 2 | 9 |
CGI-I Response rate, where response was defined as a CGI-I score of 1 or 2 (very much improved or much improved), during double-blind randomized Phase B treatment.
| Participants | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| CGI-I Response Rate | 100 | 48 | 79 |
To evaluate the safety and tolerability of brexpiprazole (flexible dose) as adjunctive therapy to ADT in the proposed subject population with MDD as AE variables.
| Participants | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| Death | 0 | 0 | 0 |
| Serious TEAE | 0 | 1 | 1 |
| Discontinuation due to TEAE | 2 | 4 | 1 |
| Any TEAE | 100 | 58 | 107 |
To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale (a self rated questionnaire) was used for measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains (work/school work, social life/leisure activities and family life/home responsibilities). All domains were rated on a score scale ranged from 0 (no impairment) to 10 (most severe). Score of 5 and above indicated significant functional impairment. A total score was addition of the 3 individual scores and the total score ranged from 0 (no impairment) to 30 (most severe).
| units on a scale | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| Work/School Score | -0.59 ± 0.16 | -0.22 ± 0.21 | -0.74 ± 0.16 |
| Social Life Score | -1.03 ± 0.13 | -0.26 ± 0.17 | -0.70 ± 0.12 |
| Family Life Score | -1.02 ± 0.13 | -0.34 ± 0.18 | -0.67 ± 0.13 |
Collected over Adverse events were recorded from screening (Day -28 to Day-1) upto post treatment follow-up.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole + ADT | 0/197 (0%) | 0/197 (0%) | 62/197 (31.5%) |
| Seroquel XR + ADT | 0/100 (0%) | 1/100 (1%) | 33/100 (33%) |
| Placebo + ADT | 0/206 (0%) | 1/206 (0.5%) | 39/206 (18.9%) |
| Event | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| malignanat melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/197 | 1/100 | 0/206 |
| panic attackPsychiatric disorders | 0/197 | 0/100 | 1/206 |
| Event | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT |
|---|---|---|---|
| SomnolenceNervous system disorders | 11/197 | 18/100 | 2/206 |
| AkathisiaNervous system disorders | 12/197 | 3/100 | 4/206 |
| HeadacheNervous system disorders | 11/197 | 1/100 | 10/206 |
| Increased AppetiteMetabolism and nutrition disorders | 5/197 | 5/100 | 2/206 |
| NasopharyngitisInfections and infestations | 9/197 | 2/100 | 9/206 |
| fatigueGeneral disorders | 3/197 | 4/100 | 3/206 |
| Weight IncreasedInvestigations | 7/197 | 4/100 | 4/206 |
| DizzinessNervous system disorders | 7/197 | 3/100 | 5/206 |
| InsomniaPsychiatric disorders | 5/197 | 3/100 | 4/206 |
| RestlessnessPsychiatric disorders | 5/197 | 1/100 | 2/206 |
Randomized sample comprised all subjects who were randomized in Phase B. Subjects were considered randomized when they were assigned a treatment number by IVRS at the end of Phase A. A subject receiving IMP outside of the IVRS was not considered randomized, but safety was reported.
| Age, Categorical(Participants) | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 197 | 100 | 206 | 503 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT | Total |
|---|---|---|---|---|
| Mean | 43.6 ± 11.5 | 44.6 ± 11.6 | 41.8 ± 11.7 | 43 ± 11.7 |
| Sex: Female, Male(Participants) | Brexpiprazole + ADT | Seroquel XR + ADT | Placebo + ADT | Total |
|---|---|---|---|---|
| Female | 128 | 66 | 149 | 343 |
| Male | 69 | 34 | 57 | 160 |
The record gives a start of Dec 2012, a primary completion of Oct 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →